282 related articles for article (PubMed ID: 23316005)
1. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
Huang XY; Ke AW; Shi GM; Zhang X; Zhang C; Shi YH; Wang XY; Ding ZB; Xiao YS; Yan J; Qiu SJ; Fan J; Zhou J
Hepatology; 2013 Jun; 57(6):2235-47. PubMed ID: 23316005
[TBL] [Abstract][Full Text] [Related]
2. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Zhang PF; Li KS; Shen YH; Gao PT; Dong ZR; Cai JB; Zhang C; Huang XY; Tian MX; Hu ZQ; Gao DM; Fan J; Ke AW; Shi GM
Cell Death Dis; 2016 Apr; 7(4):e2201. PubMed ID: 27100895
[TBL] [Abstract][Full Text] [Related]
4. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
5. Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.
Chen HA; Kuo TC; Tseng CF; Ma JT; Yang ST; Yen CJ; Yang CY; Sung SY; Su JL
Hepatology; 2016 Nov; 64(5):1637-1651. PubMed ID: 27530187
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
7. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
10. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis.
Song R; Song H; Liang Y; Yin D; Zhang H; Zheng T; Wang J; Lu Z; Song X; Pei T; Qin Y; Li Y; Xie C; Sun B; Shi H; Li S; Meng X; Yang G; Pan S; Zhu J; Qi S; Jiang H; Zhang Z; Liu L
Hepatology; 2014 Nov; 60(5):1659-73. PubMed ID: 25042864
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Nishida N; Kitano M; Sakurai T; Kudo M
Dig Dis; 2015 Oct; 33(6):771-9. PubMed ID: 26488287
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
15. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Du R; Wu S; Lv X; Fang H; Wu S; Kang J
J Exp Clin Cancer Res; 2014 Dec; 33(1):105. PubMed ID: 25499255
[TBL] [Abstract][Full Text] [Related]
17. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
Liu J; Cui X; Qu L; Hua L; Wu M; Shen Z; Lu C; Ni R
Exp Mol Pathol; 2016 Aug; 101(1):58-65. PubMed ID: 27302463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
